The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin.
 
Robert J. Jones
Research Funding - AstraZeneca (Inst)
 
Simon J. Crabb
Honoraria - Bayer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen; Pfizer; Sanofi
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Astellas Pharma; Janssen; Janssen; Novartis; Sanofi
 
John D. Chester
Research Funding - AstraZeneca (Inst)
 
Tony Elliott
Research Funding - AstraZeneca (Inst)
 
Robert Anthony Huddart
Leadership - Cancer clinic london Limited liability partnership
Honoraria - Janssen Oncology
Speakers' Bureau - AstraZeneca; Pierre Fabre
Research Funding - Active Biotech; Ipsen
Travel, Accommodations, Expenses - Janssen Oncology
 
Alison J. Birtle
No Relationships to Disclose
 
Linda Evans
No Relationships to Disclose
 
Jason Francis Lester
No Relationships to Disclose
 
Chao Huang
No Relationships to Disclose
 
Angela Claire Casbard
No Relationships to Disclose
 
Tracie-Ann Madden
No Relationships to Disclose
 
Gareth Griffiths
Consulting or Advisory Role - GlaxoSmithKline; Sirtex Medical